Abstracts tagged "Inflammation"

Abstract Number: 0930 • ACR Convergence 2024
The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts
Kaitlin Williams, Beita Badiei, Hana Minsky and Luis Garza, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses in intertriginous areas. Despite its increasing prevalence, the etiology…
Abstract Number: 1437 • ACR Convergence 2024
Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression
Sze-Lok Lau¹, Huan Meng², Isaac Cheng¹, Bryan PY Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam³, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²The Faculty of Medicine, CUHK, Hong Kong, China (People's Republic), ³The Chinese University of Hong Kong, New Territories, Hong Kong
Background/Purpose: In patients with axial spondyloarthritis (AxSpA), we have reported that higher inflammatory burden as reflected by a longer disease duration, delay in diagnosis and…
Abstract Number: 1793 • ACR Convergence 2024
SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages
Jessica Shannon and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD
Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…
Abstract Number: 2000 • ACR Convergence 2024
Induction of Systemic Inflammatory Diseases with Dupilumab Therapy
Jeanne Tisseau des Escotais¹, Camille Taille², Julie Merindol³, Matthieu Groh⁴, Perrine SMETS⁵, Amel Boudjemaa⁶, Alexandra Audemard⁷, Nabil Belfeki⁸, Philippe Bonniaud⁹, Chloe Comarmond¹⁰, Isabelle DELACROIX¹¹, Charlotte Descours¹², Lucile Grange¹³, Paul Legendre¹⁴, Nihal Martis¹⁵, Thomas Moulinet¹⁶, Béatrice Walls¹⁷, Laurent Chouchana¹ and Benjamin Terrier¹⁸, ¹Cochin, Paris, France, ²Bichat Hospital, Paris, France, ³Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, ⁴Foch, Suresnes, France, ⁵Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁶CHU créteil, Créteil, France, ⁷Tours, Tours, France, ⁸CH Melun, Melun, France, ⁹Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ¹⁰Lariboisière University Hospital, Paris, France, ¹¹CHI créteil, Créteil, France, ¹²CH Tours, Tours, France, ¹³CH Saint-Etienne, Saint-Etienne, France, ¹⁴Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, ¹⁵CH Nice, Nice, France, ¹⁶CHRU de Nancy, Vandœuvre-lès-Nancy, France, ¹⁷Paris, Paris, France, ¹⁸Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Dupilumab is a monoclonal antibody directed against the alpha subunit of the interleukin (IL)-4 receptor, blocking interleukin (IL)-4 and IL-13 signaling. It is approved…
Abstract Number: 2474 • ACR Convergence 2024
High-throughput Screening Identifies Specific Molecular Markers for ILD in Patients with Rheumatic Diseases
Anna-Maria Hoffmann-Vold¹, Vyacheslav Palchevskiy², Phuong Phuong Diep³, Henriette Didriksen¹, Mona Lovise Talaro Ramsli¹, Jin Zhou⁴, Shahrzad Lari⁴, Elena Pachera⁵, Michael T Durheim¹, Øyvind Molberg⁶, Oliver Distler⁷, S. Samuel Weigt² and John A Belperio⁴, ¹Oslo University Hospital, Oslo, Norway, ²University of California Los Angeles, Los Angeles, CA, ³Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, ⁴University of California Los Angeles, Los Angeles, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Molecular expression patterns of lung tissue across rheumatic musculoskeletal diseases (RMDs) have not been extensively studied. Lung sampling is invasive and not always practical…
Abstract Number: 2659 • ACR Convergence 2024
A Comprehensive Approach Utilizing a Combination of Genetics, Cytological Analysis, and Imaging Techniques to Speed up the Diagnostic Process in VEXAS Patients
Sara Bindoli¹, Chiara Baggio², Roberto Padoan³, Riccardo Bixio⁴, doria Andrea⁵, Roberta Ramonda² and Paolo Sfriso¹, ¹Rheumatology Unit, University of Padova, Italy, Padova, Veneto, Italy, ²Rheumatology Unit, University of Padova, Italy, Padova, Italy, ³Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, ⁴University of Verona, Verona, Verona, Italy, ⁵University of Padova, Padova, Italy
Background/Purpose: VEXAS is a newly described “haemato-autoinflammatory” condition resulting from somatic mutations in the UBA-1 gene. By integrating genetics, cytology and imaging, this work seeks…
Abstract Number: 0074 • ACR Convergence 2024
Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine², Angel Rangel-Garcia¹, Marissa Krantz³, Delaney Martino¹, Marc Nuzzo¹ and Christopher Ritchlin⁴, ¹University of Rochester, Rochester, NY, ²ORNA Tx, Southborough, MA, ³University of Rochester, Rochester, NY, ⁴Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…
Abstract Number: 0465 • ACR Convergence 2024
Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays
Monique Bastidas¹, Lythou Yeo¹, Susie Magpantay¹, Judah Scott¹, Mike Zikry¹, Wayne Galdamez¹, Jane Yang² and Kelly Chun¹, ¹Labcorp, Calabasas, CA, ²LabCorp, Weston, MA
Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…
Abstract Number: 0813 • ACR Convergence 2024
Investigating TASL, SLC15A4, & TLR7 Associated Risk SNPs in Systemic Lupus Erythematosus
Christina G. Bruxvoort¹, Faith A. Porter¹, Joshua W. Cavett¹, John A. Ice², Batool Bilal¹, R Hal Scofield¹ and Valerie M. Lewis¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OKC Veteran's Affairs Medical Center, Oklahoma City
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease that mostlyhas it onset among women between the ages 15–44. While the global pathogenic…
Abstract Number: 0936 • ACR Convergence 2024
Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis
Priyanka Kushwaha¹, Catherine Manning², Tadatoshi Sato³, Yeon-Suk Yang³, Jae-Hyuck Shim⁴ and Ellen Gravallese⁵, ¹Department of Medicine/Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, ²Brigham and Women's Hospital, Dedham, MA, ³Department of Medicine/Division of Rheumatology, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, ⁴University of Massachusetts, Worcester, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: In rheumatoid arthritis (RA), production of TNF promotes osteoclast activity and inhibits osteoblasts (OBs) and bone healing. Schnurri-3 (SHN3) is a potent suppressor of…
Abstract Number: 1473 • ACR Convergence 2024
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
M. Elaine Husni¹, Philip Mease², Dafna Gladman³, Barbara Ink⁴, Jérémy Lambert⁵, Patrick Healy⁶ and Laure Gossec⁷, ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Colombes, France, ⁶UCB Pharma, Morrisville, NC, ⁷Sorbonne Université, Paris, France
Background/Purpose: PsA is characterized by joint and skin inflammation, and associated with debilitating symptoms of pain and fatigue.1 Previous research has shown that pain and…
Abstract Number: 1794 • ACR Convergence 2024
Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus
Hanne van der Heijden¹, Andrea Knight², Itamar Ronen³, Gabrielle Alonzi⁴, Kyle McBrearty⁴, Aditi Deokar⁴, Joseph Gonzalez-Heydrich⁴, Joyce Chang⁴ and Jaymin Upadhyay⁵, ¹Boston Children's Hospital Harvard Medical School, Boston, MA, ²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Brighton and Sussex Medical School, University of Sussex, Brighton, UK, Brighton, United Kingdom, ⁴Boston Children's Hospital, Boston, MA, ⁵Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Cognitive dysfunction (CD) in childhood-onset SLE (cSLE) is undertreated yet profoundly impacts lifelong health-related quality of life. Investigating CD in cSLE is crucial, given…
Abstract Number: 2002 • ACR Convergence 2024
Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Laura Cappelli¹, Cyd Eaton¹, Yunzhi Wang¹, Michelle Jones² and Clifton Bingham³, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins School of Medicine, Pittsburgh, PA, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an impactful and often persistent side effect of cancer immunotherapy that can lead to permanent joint damage…
Abstract Number: 2511 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Patients with Clinically Isolated Aortitis
Mahmut Kaymakci¹, Hannah Langenfeld¹, Andrew C. Hanson², Cynthia Crowson¹, Melanie Bois¹, Hartzell Schaff², Mohanad Elfishawi³, Matthew Koster¹, Cornelia Weyand² and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³University of Minnesota, Minneapolis
Background/Purpose: Clinically Isolated Aortitis (CIA) is a type of vasculitis affecting the aorta in the absence of systemic vasculitis, rheumatic disease, or infection. Most patients…
Abstract Number: 2690 • ACR Convergence 2024
ANCA IgG Promotion of Neutrophil Recruitment, Migration and Vascular Damage in ANCA Associated Vasculitis May Be Enhanced by Hypoxia
Noelle Pisacano, Amrita Dhutia, Stephen Rothery, Charles Pusey, Edwin Chilvers, Andrew Cowburn, Katharine Lodge and Maria Prendecki, Imperial College London, London, United Kingdom
Background/Purpose: Neutrophils are main mediators of disease in ANCA associated vasculitis (AAV). Pathogenic ANCA IgG on neutrophils promotes neutrophil adhesion and migration at the endothelium.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].